[{"id":"8d2fd6b3-99fe-4b7c-a171-d1e7a5b2b2a9","acronym":"ENFORCE","url":"https://clinicaltrials.gov/study/NCT01810705","created_at":"2021-01-18T08:01:47.336Z","updated_at":"2024-07-02T16:36:16.865Z","phase":"Phase 2b","brief_title":"GRASPA Treatment for Patients With Acute Myeloblastic Leukemia","source_id_and_acronym":"NCT01810705 - ENFORCE","lead_sponsor":"ERYtech Pharma","biomarkers":" ASNS","pipe":"","alterations":" ","tags":["ASNS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Graspa (eryaspase)"],"overall_status":"Completed","enrollment":" Enrollment 123","initiation":"Initiation: 02/01/2013","start_date":" 02/01/2013","primary_txt":" Primary completion: 11/10/2017","primary_completion_date":" 11/10/2017","study_txt":" Completion: 11/10/2017","study_completion_date":" 11/10/2017","last_update_posted":"2022-02-21"},{"id":"98093373-bb38-49b2-ab54-0f82bc015fbc","acronym":"","url":"https://clinicaltrials.gov/study/NCT01523808","created_at":"2021-10-15T22:53:09.067Z","updated_at":"2024-07-02T16:36:22.983Z","phase":"Phase 1","brief_title":"Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase)in Patients With Pancreatic Cancer","source_id_and_acronym":"NCT01523808","lead_sponsor":"ERYtech Pharma","biomarkers":" CEACAM5","pipe":"","alterations":" ","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Graspa (eryaspase)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 11/01/2009","start_date":" 11/01/2009","primary_txt":" Primary completion: 03/01/2011","primary_completion_date":" 03/01/2011","study_txt":" Completion: 03/01/2011","study_completion_date":" 03/01/2011","last_update_posted":"2021-10-15"},{"id":"dd0cb067-9e6d-4806-b78d-9c53942826a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02195180","created_at":"2021-01-18T10:15:55.266Z","updated_at":"2024-07-02T16:37:08.554Z","phase":"Phase 2","brief_title":"Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma","source_id_and_acronym":"NCT02195180","lead_sponsor":"ERYtech Pharma","biomarkers":" ASNS","pipe":"","alterations":" ","tags":["ASNS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • oxaliplatin • leucovorin calcium • Graspa (eryaspase)"],"overall_status":"Completed","enrollment":" Enrollment 141","initiation":"Initiation: 07/01/2014","start_date":" 07/01/2014","primary_txt":" Primary completion: 02/01/2017","primary_completion_date":" 02/01/2017","study_txt":" Completion: 11/01/2017","study_completion_date":" 11/01/2017","last_update_posted":"2018-07-27"}]